Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xing Niu

Showing results (91-100 of 93) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 93 results.
CA: a Cancer Journal for Clinicians|February 27, 2026
Global cancer statistics for children: Two decades of change and projections to 2050Wangzhong Li, Shanzhou Huang, Qiyue Chen, et al.
Chinese Medical Journal|July 31, 2018
Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional StudyJian-Qiu Wu, Yong-Ping Song, Li-Ping Su, et al.
Nature Medicine|July 16, 2025
The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trialDan-Yun Ruan, Hao-Xiang Wu, Su-Xia Luo, et al.
Pageof 10

Showing results (91-100 of 93) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 93 results.
CA: a Cancer Journal for Clinicians|February 27, 2026
Global cancer statistics for children: Two decades of change and projections to 2050Wangzhong Li, Shanzhou Huang, Qiyue Chen, et al.
Chinese Medical Journal|July 31, 2018
Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional StudyJian-Qiu Wu, Yong-Ping Song, Li-Ping Su, et al.
Nature Medicine|July 16, 2025
The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trialDan-Yun Ruan, Hao-Xiang Wu, Su-Xia Luo, et al.
Pageof 10